Oppenheimer & Co. Inc. Boosts Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Oppenheimer & Co. Inc. grew its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 52.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 104,231 shares of the biotechnology company’s stock after purchasing an additional 35,823 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Capricor Therapeutics were worth $1,438,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CAPR. Black Diamond Financial LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter worth about $3,833,000. Point72 Asset Management L.P. purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $3,806,000. PFM Health Sciences LP purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $2,324,000. State Street Corp boosted its holdings in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $938,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $13.67 on Tuesday. The firm has a market cap of $621.57 million, a P/E ratio of -12.90 and a beta of 4.08. The stock has a 50 day simple moving average of $14.42 and a two-hundred day simple moving average of $13.80. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.